Blood Test Helps Determine Traumatic Brain Injury Severity
|
By LabMedica International staff writers Posted on 11 Aug 2015 |

Image: Three-dimensional structure of the brain-derived neurotrophic factor protein (Photo courtesy of Microswitch/ Protein Data Bank).
A new blood test could help emergency room doctors quickly diagnose traumatic brain injury and determine its severity and the test could help identify patients who might benefit from extra therapy or novel treatments.
Brain derived neurotrophic factor (BDNF) is important for neuronal survival and regeneration the diagnostic and prognostic values of serum BDNF in traumatic brain injury (TBI) and its association with two other proteins has been investigated.
A large group of collaborating scientists led by those at Johns Hopkins University School of Medicine (Baltimore, MD, USA) examined serum BDNF in two independent cohorts of TBI cases presenting to the emergency departments. At Johns Hopkins Hospital, 76 patients were studied and at San Francisco General Hospital (CA, USA), 80 patient were included in the study and a control group of 150 patients without TBI were enrolled.
The teams investigated the association between BDNF, Glial fibrillary acidic protein (GFAP) and Ubiquitin C-terminal hydrolase -L1 (UCH-L1) and recovery from TBI at six months in a pilot cohort. The investigators found that the levels of BDNF, taken within 24 hours of someone's head injury, could predict the severity of a TBI and how a patient would fare. While healthy people averaged 60 ng/mL of BDNF in their bloodstreams, patients with brain injuries had less than one-third of that amount, averaging less than 20 ng/mL, and those with the most severe TBIs had even lower levels, around 4 ng/mL. Moreover, patients with high levels of BDNF had mostly recovered from their injuries six months later, but in patients with the lowest levels of BDNF, symptoms still lingered at follow-up. The results suggest that a test for BDNF levels, administered in the emergency room, could help stratify patients.
Frederick Korley, MD, PhD, an assistant professor of emergency medicine and first author of the study said, “Compared to other proteins that have been measured in traumatic brain injury, BDNF does a much better job of predicting outcomes. The advantage of being able to predict prognosis early on is that you can advise patients on what to do, recommend whether they need to take time off work or school, and decide whether they need to follow up with a rehab doctor or neurologist.” The study was published on July 10, 2015, in the Journal of Neurotrauma.
Related Links:
Johns Hopkins University School of Medicine
San Francisco General Hospital
Brain derived neurotrophic factor (BDNF) is important for neuronal survival and regeneration the diagnostic and prognostic values of serum BDNF in traumatic brain injury (TBI) and its association with two other proteins has been investigated.
A large group of collaborating scientists led by those at Johns Hopkins University School of Medicine (Baltimore, MD, USA) examined serum BDNF in two independent cohorts of TBI cases presenting to the emergency departments. At Johns Hopkins Hospital, 76 patients were studied and at San Francisco General Hospital (CA, USA), 80 patient were included in the study and a control group of 150 patients without TBI were enrolled.
The teams investigated the association between BDNF, Glial fibrillary acidic protein (GFAP) and Ubiquitin C-terminal hydrolase -L1 (UCH-L1) and recovery from TBI at six months in a pilot cohort. The investigators found that the levels of BDNF, taken within 24 hours of someone's head injury, could predict the severity of a TBI and how a patient would fare. While healthy people averaged 60 ng/mL of BDNF in their bloodstreams, patients with brain injuries had less than one-third of that amount, averaging less than 20 ng/mL, and those with the most severe TBIs had even lower levels, around 4 ng/mL. Moreover, patients with high levels of BDNF had mostly recovered from their injuries six months later, but in patients with the lowest levels of BDNF, symptoms still lingered at follow-up. The results suggest that a test for BDNF levels, administered in the emergency room, could help stratify patients.
Frederick Korley, MD, PhD, an assistant professor of emergency medicine and first author of the study said, “Compared to other proteins that have been measured in traumatic brain injury, BDNF does a much better job of predicting outcomes. The advantage of being able to predict prognosis early on is that you can advise patients on what to do, recommend whether they need to take time off work or school, and decide whether they need to follow up with a rehab doctor or neurologist.” The study was published on July 10, 2015, in the Journal of Neurotrauma.
Related Links:
Johns Hopkins University School of Medicine
San Francisco General Hospital
Latest Clinical Chem. News
- Blood Test Could Predict and Identify Early Relapses in Myeloma Patients
- Compact Raman Imaging System Detects Subtle Tumor Signals
- Noninvasive Blood-Glucose Monitoring to Replace Finger Pricks for Diabetics
- POC Breath Diagnostic System to Detect Pneumonia-Causing Pathogens
- Online Tool Detects Drug Exposure Directly from Patient Samples
- Chemical Imaging Probe Could Track and Treat Prostate Cancer
- Mismatch Between Two Common Kidney Function Tests Indicates Serious Health Problems
- VOCs Show Promise for Early Multi-Cancer Detection
- Portable Raman Spectroscopy Offers Cost-Effective Kidney Disease Diagnosis at POC
- Gold Nanoparticles to Improve Accuracy of Ovarian Cancer Diagnosis
- Simultaneous Cell Isolation Technology Improves Cancer Diagnostic Accuracy
- Simple Non-Invasive Hair-Based Test Could Speed ALS Diagnosis
- Paper Strip Saliva Test Detects Elevated Uric Acid Levels Without Blood Draws
- Prostate Cancer Markers Based on Chemical Make-Up of Calcifications to Speed Up Detection
- Breath Test Could Help Detect Blood Cancers
- ML-Powered Gas Sensors to Detect Pathogens and AMR at POC
Channels
Molecular Diagnostics
view channel
At-Home Blood Tests Accurately Detect Key Alzheimer's Biomarkers
Diagnosing Alzheimer’s disease typically relies on brain scans or spinal fluid tests, which are invasive, costly, and difficult to access outside specialist clinics. These barriers have limited large-scale... Read more
Blood Test Combined with MRI Brain Scans Reveals Two Distinct Multiple Sclerosis Types
Multiple sclerosis (MS) affects more than 2.8 million people worldwide, yet predicting how the disease will progress in individual patients remains difficult. Current MS classifications are based on clinical... Read more
Ultra-Sensitive Blood Biomarkers Enable Population-Scale Insights into Alzheimer’s Pathology
Accurately estimating how many people carry Alzheimer’s disease pathology has long been a challenge, as traditional methods rely on small, clinic-based samples rather than the general population.... Read more
Blood Test Could Predict Death Risk in World’s Most Common Inherited Heart Disease
Hypertrophic cardiomyopathy (HCM) is the world’s most common inherited heart condition and affects millions of people globally. While some patients live with few or no symptoms, others develop heart failure,... Read moreHematology
view channel
MRD Tests Could Predict Survival in Leukemia Patients
Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more
Platelet Activity Blood Test in Middle Age Could Identify Early Alzheimer’s Risk
Early detection of Alzheimer’s disease remains one of the biggest unmet needs in neurology, particularly because the biological changes underlying the disorder begin decades before memory symptoms appear.... Read more
Microvesicles Measurement Could Detect Vascular Injury in Sickle Cell Disease Patients
Assessing disease severity in sickle cell disease (SCD) remains challenging, especially when trying to predict hemolysis, vascular injury, and risk of complications such as vaso-occlusive crises.... Read more
ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners
Direct oral anticoagulants (DOACs) are one of the most common types of blood thinners. Patients take them to prevent a host of complications that could arise from blood clotting, including stroke, deep... Read moreImmunology
view channel
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read more
Blood Test Could Identify Colon Cancer Patients to Benefit from NSAIDs
Colon cancer remains a major cause of cancer-related illness, with many patients facing relapse even after surgery and chemotherapy. Up to 40% of people with stage III disease experience recurrence, highlighting... Read moreMicrobiology
view channel
New UTI Diagnosis Method Delivers Antibiotic Resistance Results 24 Hours Earlier
Urinary tract infections affect around 152 million people every year, making them one of the most common bacterial infections worldwide. In routine medical practice, diagnosis often relies on rapid urine... Read more
Breakthroughs in Microbial Analysis to Enhance Disease Prediction
Microorganisms shape human health, ecosystems, and the planet’s climate, yet identifying them and understanding how they are related remains a major scientific challenge. Even with modern DNA sequencing,... Read morePathology
view channel
ADLM Updates Expert Guidance on Urine Drug Testing for Patients in Emergency Departments
Urine drug testing plays a critical role in the emergency department, particularly for patients presenting with suspected overdose or altered mental status. Accurate and timely results can directly influence... Read more
New Age-Based Blood Test Thresholds to Catch Ovarian Cancer Earlier
Ovarian cancer affects around one in 50 women during their lifetime, with roughly 7,000 diagnoses each year in the UK. The disease is often detected late because symptoms such as bloating, abdominal pain,... Read moreTechnology
view channel
Pioneering Blood Test Detects Lung Cancer Using Infrared Imaging
Detecting cancer early and tracking how it responds to treatment remains a major challenge, particularly when cancer cells are present in extremely low numbers in the bloodstream. Circulating tumor cells... Read more
AI Predicts Colorectal Cancer Survival Using Clinical and Molecular Features
Colorectal cancer is one of the most common and deadly cancers worldwide, and accurately predicting patient survival remains a major clinical challenge. Traditional prognostic tools often rely on either... Read moreIndustry
view channel
BD and Penn Institute Collaborate to Advance Immunotherapy through Flow Cytometry
BD (Becton, Dickinson and Company, Franklin Lakes, NJ, USA) has entered into a strategic collaboration with the Institute for Immunology and Immune Health (I3H, Philadelphia, PA, USA) at the University... Read more







